Zdrowie i gospodarka · 03/07/2018
FDA Announces Public Comment Period for Biosimilar Information Collection
The Food and Drug Administration (FDA) is seeking public input on proposed information collection requirements for biosimilar product applications and supplement requests, as mandated by the Paperwork Reduction Act of 1995.
Source: Federal Register — Food and Drug AdministrationOpen original release →